328 related articles for article (PubMed ID: 12838665)
21. Susceptibility patterns of Candida species recovered from Canadian intensive care units.
Laverdiere M; Labbé AC; Restieri C; Rotstein C; Heyland D; Madger S; Stewart T
J Crit Care; 2007 Sep; 22(3):245-50. PubMed ID: 17869976
[TBL] [Abstract][Full Text] [Related]
22. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole.
Hsueh PR; Teng LJ; Yang PC; Ho SW; Luh KT
Microb Drug Resist; 2002; 8(4):311-9. PubMed ID: 12523628
[TBL] [Abstract][Full Text] [Related]
23. Molecular typing of Candida isolates from patients hospitalized in an intensive care unit.
Vrioni G; Matsiota-Bernard P
J Infect; 2001 Jan; 42(1):50-6. PubMed ID: 11243754
[TBL] [Abstract][Full Text] [Related]
24. Candida albicans in a neonatal intensive care unit: antifungal susceptibility and genotypic analysis.
Asticcioli S; Nucleo E; Perotti G; Matti C; Sacco L; Pagani L
New Microbiol; 2007 Jul; 30(3):303-7. PubMed ID: 17802915
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations.
Xu Y; Chen L; Li C
J Antimicrob Chemother; 2008 Apr; 61(4):798-804. PubMed ID: 18218640
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
28. [The relationship between Candida albicans 25S intron genotypes and antifungal susceptibilities].
Balaban N; Karahan ZC; Mumcuoğlu I; Cayirli A; Kuştimur S
Mikrobiyol Bul; 2007 Apr; 41(2):245-51. PubMed ID: 17682711
[TBL] [Abstract][Full Text] [Related]
29. [Epidemiological study of invasive nosocomial candidiasis in 2 teaching hospitals in Beijing].
Cao B; Wang H; Wu L; Sun WJ; Li F; Liu YM
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1970-3. PubMed ID: 19062737
[TBL] [Abstract][Full Text] [Related]
30. [Investigation of quantitative and species composition and antifungal drug susceptibility of yeasts isolated from patients with generalized periodontitis complicated by candidosis].
Kutsyk RV; Pavliuk TD
Mikrobiol Z; 2003; 65(5):26-9. PubMed ID: 14723159
[TBL] [Abstract][Full Text] [Related]
31. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
32. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
33. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
34. Molecular assay to detect nosocomial fungal infections in intensive care units.
Badiee P; Alborzi A; Joukar M
Eur J Intern Med; 2011 Dec; 22(6):611-5. PubMed ID: 22075290
[TBL] [Abstract][Full Text] [Related]
35. [The value of the agar dilution method as a screening test for determining the sensitivity of Candida albicans to fluconazole].
Yücesoy M; Marol S
Mikrobiyol Bul; 2002; 36(3-4):317-22. PubMed ID: 12838666
[TBL] [Abstract][Full Text] [Related]
36. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
37. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
38. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
40. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
